Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15376 - 15400 of 15745 in total
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to...
Investigational
Matched Description: … pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to test the safety and
Experimental
Adagloxad simolenin is under investigation in clinical trial NCT03562637 (Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC).
Investigational
RO6874281 is under investigation in clinical trial NCT03193190 (A Study of Multiple Immunotherapy-based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-pancreatic Cancer)).
Investigational
IONIS-HBVRx is under investigation in clinical trial NCT04544956 (A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B).
Investigational
B27PD is under investigation in clinical trial NCT01195948 (Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis).
Investigational
siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Investigational
BGB-DXP593 is a SARS-CoV-2 neutralizing antibody. It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)) by BeiGene.
Investigational
Experimental
Experimental
Experimental
Experimental
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
Investigational
Etokimab is under investigation in clinical trial NCT03614923 (Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)).
Investigational
Mibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy).
Investigational
Investigational
Investigational
Displaying drugs 15376 - 15400 of 15745 in total